To date, there are no vasopressin (VP) agonists that exhibit a high affinity and selectivity for the VP V 1b receptor with respect to the V 1a , V 2 , and oxytocin receptors. In this study, we describe the synthesis and pharmacological properties of thesized by supraoptic and paraventricular hypothalamic neurons. Released in the general circulation and in the hypophysial portal system, it exerts three main physiological actions: vasoconstriction, antidiuresis, and ACTH secretion (1). Besides these well-documented effects, VP also regulates other functions like liver glycogenolysis (1), steroid and catecholamine secretion by the adrenals (2), insulin and glucagon release by the pancreas (3), and heart atrial natriuretic factor secretion (4). VP is also supposed to regulate numerous central functions like synaptic transmission, central control of body temperature, memory, and more recently, anxiety and depression behaviors in the rat (for review see Refs. 5 and 6).
I N MAMMALS, VASOPRESSIN (VP) is a nonapeptide syn-
thesized by supraoptic and paraventricular hypothalamic neurons. Released in the general circulation and in the hypophysial portal system, it exerts three main physiological actions: vasoconstriction, antidiuresis, and ACTH secretion (1) . Besides these well-documented effects, VP also regulates other functions like liver glycogenolysis (1), steroid and catecholamine secretion by the adrenals (2), insulin and glucagon release by the pancreas (3), and heart atrial natriuretic factor secretion (4) . VP is also supposed to regulate numerous central functions like synaptic transmission, central control of body temperature, memory, and more recently, anxiety and depression behaviors in the rat (for review see Refs. 5 and 6).
All these effects are triggered by specific VP receptors belonging to the G protein-coupled receptor family. Only three distinct isoforms have been described and cloned in numerous mammalian species (for review see Ref. 7) . Historically, classification of VP receptors was established in 1978 by Michell on the basis of their second messenger pathways (8) . VP receptors from liver positively coupled to phospholipase C␤ via ␣q/11 heterotrimeric G proteins are called V 1 receptors. Renal VP receptors activate adenylyl cyclase (AC) via ␣s G protein and are called V 2 receptors. They exhibit a pharmacological profile distinct from those of V 1 receptors (for review see Ref. 1) .
The classification of VP receptor isoforms has been improved by the availability of numerous VP radioligands and VP structural analogs (7, 9) . Thus, two distinct V 1 receptor subtypes have been characterized on the basis of their affinities for cyclopentamethylene VP antagonists: V 1a -R are those responsible for the pressor and the glycogenolytic effects; V 1b -R present principally at the pituitary level and induce ACTH secretion (10) . At the present time, peptide and nonpeptide agonists or antagonists of V 1a and V 2 receptors exhibiting a good affinity have been described (7, 9) . For example, SR49059 and d[(CH 2 ) 5 Tyr(Me 2 )]AVP are both potent and selective V 1a antagonists with nanomolar affinities in various species (7) . Similarly, SR121463 is the best selective V 2 antagonist described, exhibiting a good affinity (7) . The design of such selective compounds has led to the development of useful tools for physiological studies and are also of potential therapeutic interest. Thus, several specific nonpeptide antagonists of human V 2 and V 1a receptors are currently in clinical trials (7, 9) .
To date, no specific VP agonists with both high affinity and selectivity for the V 1b receptor with respect to either V 1a or V 2 receptors are available. On the basis of in vivo bioassays, Schwartz and collaborators (11) designed a synthetic VP analog modified in position 2: d[d-3-Pal 2 ]AVP. In the rat, this compound is a weak antidiuretic agonist and a weak antagonist of the vasoconstrictor responses. In dissociated ovine pituitary cells, it maximally stimulates ACTH release with the same efficiency but with a reduced affinity compared with VP. Yet, binding studies performed on human VP receptors indicate that this V 1b agonist is totally nonselective with respect to V 1a receptors (for review see Ref. 7) . Very recently, Serradeil le-Gal and collaborators (6) described a novel nonpeptide antagonist, SSR149415, exhibiting a good affinity and selectivity for both human and rat V 1b receptors. Using this V 1b antagonist, they demonstrated that VP, by acting on central V 1b receptors, may control anxiety and depression behaviors in rats.
In this study, we describe both on native and transfected biological models, the binding and functional properties of d [Cha 4 ]AVP, the first specific V 1b /V 1a agonist in rat, human, and bovine species. This peptide is also the first specific V 1b /V 2 agonist in human and bovine species. We also present affinity data for the rat, bovine, and human V 1a , V 1b , V 2 
Membrane preparations from liver, kidney, and anterior pituitaries
These were obtained as previously described (15) from adult female Wistar rats (175-200 g) purchased from Iffa Credo (l'Arbresle France) and from tissues of young bovines freshly collected in a slaughterhouse. Animal manipulations were performed according to the recommendations of the French Ethical Committee and under the supervision of authorized investigators.
Chinese hamster ovary (CHO) cell culture and membrane preparation
Membranes from CHO cell lines stably transfected with the human V 1a , V 1b , V 2 , and OT receptors (hV 1a -R, hV 1b -R, hV 2 -R, and hOT-R, respectively) were prepared as previously described (16) .
Binding assays
Membrane incubations with VP radioligands were performed as previously described (15 125 I]-OTA were added in the incubation medium for V 1a , V 1b , V 2 , or OT receptor measurements, respectively, with (nonspecific binding) or without (total binding) 1 m of unlabeled AVP or OT and increasing amounts of the unlabeled analogs to be tested. Radioactivity found associated to plasma membranes was determined by filtration through GF/C filters as previously described (15) . Specific binding was calculated in each condition and expressed as percent of the maximal binding capacity determined without unlabeled analog.
Chromaffin cells primary culture and catecholamine release assays
Culture of bovine chromaffin cells were cultured according to Wilson and Viveros (17) . Briefly, adrenal glands from young bovine animals (1-3 months) were perfused through the adrenal vein with a Locke buffer complemented with 1 mg⅐ml Ϫ1 collagenase I and 0.1 mg⅐ml
Ϫ1
DNase IV. The medulla part of the adrenal gland was separated from cortex, minced, and digested in the same Locke/collagenase/DNase medium. Cells subsequently dissociated were purified on a Percoll density gradient and plated on collagen-coated dishes. Cells were maintained in a DMEM/F-12 nutrient medium in a 95%O 2 /5%CO 2 atmosphere and used for experiments 1 d after. The purity of this primary culture (80% of chromaffin cells) was estimated by morphological and functional criteria (calcium mobilization induced by nicotine application). Catecholamines release was measured as previously described (18) . Briefly, chromaffin cells were loaded with 4 Ci⅐ml Ϫ1 [ 3 H]-norepinephrine in the DMEM/F-12 medium complemented with 5 mm ascorbic acid. After a 2-to 4-h loading period, cells were washed in a Hanks' buffered saline (HBS), further incubated for 6 min at 25 C with or without the analogs to be tested. The incubation medium was collected, and 
Culture of rat adenohypophysial cells and ACTH release measurements
Adenohypophysial cells from 12-20 pituitaries were prepared as previously described (10) . Briefly, cells were dissociated using a collagenase/dispase medium, washed, and plated at a density of 0.6 -0. 8 10 6 cells per well in a culture medium containing a DMEM/F-12/BGJB nutrient medium supplemented with 2 mg⅐ml Ϫ1 BSA, 2.38 mg⅐ml
Ϫ1
HEPES, 50 mg⅐liter Ϫ1 gentamycin, 10 mg⅐liter Ϫ1 transferrin, and 2.5% fetal calf serum. After 4 d in primary culture, cells were washed with a serum-free culture medium and then incubated for 3 h in 1 ml of this medium, with or without (control) the analogs to be tested. The medium was then collected and stored frozen at -20 C until ACTH determination. ACTH secretion was determined by RIA as previously published (10) .
Inositol phosphate (IP) assays
IP accumulation was determined as previously described (19) . Briefly, CHO cells stably transfected with the human V 1b -R or WRK1 cells that naturally expressed rat V 1a -R (20) were plated at 20,000 cells/ dishes. Cells were grown for 48 h in DMEM supplemented with 10% fetal calf serum (CHO cells) and MEM supplemented with 5% fetal calf serum/2% rat serum (WRK1 cells). Cells were further incubated for another 24-h period in a serum and inositol-free medium supplemented with 1 Ci⅐ml Ϫ1 myo- [2- 3 H]-inositol. Cells were then washed twice with HBS, equilibrated at 37 C in HBS for 30 min, and incubated for 15 min in HBS supplemented with 10 mm LiCl. Cells were then stimulated for 15 min with increasing concentrations of analogs to be tested. Reaction was stopped with 5% (vol/vol) perchloric acid. Total inositol IPs accu-mulated were extracted and purified on Dowex AG1-X8 anion exchange chromatography column and counted.
Adenylate cyclase assays
Adenylate cyclase activity was assessed as previously described (21) 
In vivo bioassays
The influence of d [Cha 4 ]AVP injections in anesthetized rats was tested on vasopressor and antidiuretic responses and on its ability to stimulate ACTH and corticosterone secretion. Antidiuretic assays were performed on water-loaded rats under anesthesia as described by Sawyer (22) . Vasopressor assays were performed on urethane-anesthetized and phenoxybenzamine-treated rats as described by Dekanski (23) . Synthetic AVP, which had been standardized in vasopressor units against the USP Posterior Pituitary Reference Standard, was used as a working standard in these two bioassays.
In vivo ACTH and corticosterone secretion measurements were performed as previously described by Aizawa et al. (24) with some minor modifications. Rats were anesthetized with Ketalar (17.5 mg ketamine plus 0.5 mg xylasin/100 g body weight, BW). Analogs to be tested were injected in the jugular vein 1 h after anesthesia. Blood samples (0.3 ml) were collected from the jugular vein just before (0) and at 5, 15, and 30 min after injection of the analogs tested. ACTH and corticosterone secretions were determined by immunoradiometric as previously modified and validated for the rat (25) .
Data analysis
The radioligand binding data were analyzed by GraphPad Software, Inc. Prism (GraphPad Software, Inc., San Diego, CA). The inhibitory dissociation constants (K i ) for unlabeled AVP analogs were calculated from binding competition experiments according to the Cheng and Prusoff (25a) equation: 
Results

Synthesis of d[Cha 4 ]AVP and d[D-Phe 2 ]AVP
The protected precursor required for the synthesis of d [Cha 4 ]AVP was prepared by the manual solid-phase method (26) starting from Boc-Gly-resin, following previously described procedures (13, 27, 28) . Successive cycles of deprotection, neutralization, and coupling gave the protected acyloctapeptide resin. Ammonolysis in methanol (13, 27, 28) An aliquot of the protected precursor (A) (150 mg) was reduced with Na/liquid NH 3 (29) , cyclized with potassium ferricyanide by the reverse procedure (30) and the crude peptide was purified in a two-step procedure involving gel filtration on Sephadex G-15 (31) in 50% acetic acid, and on Sephadex LH-20 in 0.2 n acetic acid as previously described (28) . The final lyophilization gave the desired product MprTyr-Phe-Cha-Asn-Cys-Pro-Arg-Gly-NH 2 
Rationale for designing selective V 1b VP analogs
As illustrated in Table 1 (32) . It should also be noted that this peptide had earlier been shown to exhibit corticotropinreleasing factor (CRF) activity in the rat (24) . These findings prompted our examination of the receptor affinities of the previously published selective antidiuretic agonist d [Val 4 ]AVP (13) reported here ( Table 2 ). d [Val 4 ]AVP was found to exhibit high affinities for the human and rat V 1b receptors, whereas it exhibited diminished affinities for the human and rat V 1a receptors. These findings prompted a further investigation of position 4 in dAVP with a variety of aliphatic amino acids (Manning, M., S. Derick, and G. Guillon, unpublished results). These studies led to the discovery of d [Cha 4 ]AVP being reported here.
Binding properties of d[Cha 4 ]AVP on vasopressin and oxytocin receptors
The binding affinities for human, rat and bovine VP and OT receptors are presented in Table 2 . As shown in Fig. 1 Binding assays were performed as described in Materials and Methods on plasma membranes from CHO cells stably transfected with the human AVP receptors and from rat tissues naturally expressing VP receptors subtypes. K i values are mean Ϯ SEM obtained from at least three independent experiments performed in triplicate. V 1b -S.I., V 1b -normalized selectivity index ϭ (K i analog for V X -R/K i AVP for V X -R)/(K i analog for V 1b -R/K i AVP for V 1b -R). 
Functional properties of d[Cha 4 ]AVP on native biological models and CHO cells expressing V 1b receptors
We decided to determine the functional properties of d [Cha 4 ]AVP on rat pituitary cells, which are known to secrete ACTH upon V 1b receptor stimulation (10) . As shown in Fig. 2A, d 4 ]AVPϭ 83% of maximal AVP effect, n ϭ 5) ( Table 3) . AVP is also known to potentiate CRF-induced ACTH secretion by corticotrophs (33) . Thus, we verified if such synergism occurred using our selective (Fig. 2B) .
We also verified the agonist properties of d [Cha 4 ]AVP on CHO cell lines stably transfected with human V 1b receptors. Both AVP and d [Cha 4 ]AVP stimulated total IPs accumulation in a dose-dependent manner (Fig. 2C) . On these cells, d [Cha 4 ]AVP was slightly less efficient than AVP to induce IPs accumulation (Table 3 ) (maximal d [Cha 4 ]AVP-induced IPs accumulation ϭ 88% of maximal AVP effect; n ϭ 4).
As V 1b receptors are also expressed in peripheral organs, we decided to validate the properties of d [Cha 4 ]AVP on a native extrapituitary V 1b receptor model: the adrenal medulla. We previously demonstrated that V 1b receptors are present in rat and human adrenal medulla and involved in catecholamine release (34) . Such receptors are also present in bovine adrenomedullary chromaffin cells and modulate the same biological activity (Andrès, M., unpublished results). d [Cha 4 ]AVP, like AVP, dose dependently stimulated catecholamine release, and its maximal activity was 80% (n ϭ 4) of those measured with maximal doses of AVP (Fig. 2D and Table 3 ). 4 ]AVP on native biological models expressing rat V 1a and V 2 
Functional properties of d[Cha
vasopressin receptors
To further characterize the functional properties of d [Cha 4 ]AVP on other rat VP receptor isoforms and evaluate its V 1b selectivity, we measured its ability to stimulate the V 1a and V 2 receptors transduction pathways.
On WRK1 cells, a rat mammary tumor cell line that expresses V 1a receptors (20) , AVP dose dependently stimulated IPs accumulation with a K act of 0.94 Ϯ 0.01 nm (n ϭ 3) (Fig. 3,  left panel nm (n ϭ 3). On rat kidney plasma membranes derived from the medulla, a structure known to express V 2 receptors physiologically involved in water reabsorption (21), AVP stimulated AC activity in a dose-dependent manner with a K act of 0.54 Ϯ 0.20 nm (n ϭ 3) (Fig. 3, right panel) 4 ]AVP is thus as efficient that AVP to induce a stress response. Interestingly, modification of dAVP, which exhibits the same CRF activity as AVP (24) , at position 4 by cyclohexylalanine, does not alter its CRF activity. This is at variance with the effects of this modification on antidiuretic and vasopressor activities ( Table 4 ). The high V 1b /V 1a selectivity in vivo and in vitro for rat receptors makes d [Cha 4 ]AVP a valuable research tool for discriminating between both receptor isoforms in this species.
Up to now, studies concerning potential new physiological effects of VP mediated by V 1b receptors have been hampered by the lack of specific V 1b agonists or antagonists. The presence of V 1b receptors in various regions of rat brain has been demonstrated using the in situ hybridization method (38) or more recently, with a V 1b receptor polyclonal antibody (39) . Their physiological involvement remains to be elucidated. Using a new specific V 1b antagonist, a major role of VP and central V 1b receptors in depression and anxiety has recently been strongly suggested (6) . Intracerebroventricular injection of SSR149415 in rat brain was shown to reduce the depressive and anxious behaviors of animals treated with AVP. These striking observations confirmed previous studies obtained in humans and rats. In depressed patients, it was shown that the number of hypothalamic neurons coexpressing VP and CRF is strongly increased (40) . This observation seems correlated to the high percentage of depressed patients presenting with high levels of circulating ACTH and corticotrope axis hyperactivity (41) . Moreover, VP plasma concentration is strongly increased in this disease (42) . Similarly, in the rat, induced-chronic stress increases the circulating level of ACTH and corticosterone and also the density of pituitary VP receptors (43, 44) . The availability of the selective V 1b ligand d [Cha 4 ]AVP as a new pharmacological tool now makes possible the study of these physiological effects in the rat.
In conclusion, our studies demonstrate that d [Cha 4 ]AVP is the first specific VP agonist that exhibits a nanomolar affinity for mammalian V 1b receptors. Furthermore, it exhibits a good V 1b /V 1a selectivity for the rat VP receptors and excellent V 1b /V 1a and V 1b /V 2 selectivities for the human and bovine VP receptors. d [Cha 4 ]AVP is thus a promising new pharmacological tool. Together with the recently reported nonpeptide selective V 1b antagonist SSR149415 (6), d [Cha 4 ]AVP could provide important new insights for V 1b receptor structure/function investigations and may lead to a better understanding of V 1b -mediated vasopressin actions, especially in the field of depression.
